New Therapeutic Pipeline Program Grant from the Michael J. Fox Foundation to block inflammasome-induced neuroinflammation in Parkinson's disease
Part of the research team who discovered MCC950 - a small molecule inflammasome inhibitor - has been awarded a Therapeutic Pipeline Program Grant from the Michael J. Fox Foundation for Parkinson's Research.
This project will reveal how the body produces interleukin-1β – a protein at the heart of inflammation and disease – so we can design better strategies for treating patients with inflammation driven disease
We are excited to announce that Associate Professor Kate Schroder, has been awarded funding to explore a novel mechanism for IL-1β secretion.Th
"There is mounting evidence that people with Parkinson’s develop brain inflammation, which accompanies the loss of dopamine-producing brain cells seen in the disease. Our aim is to find a medication that will target the immune response that causes inflammation in the brain, to slow down and hopefully halt disease progression. Our hope for the future is to take these drugs into human clinical trials for Parkinson’s treatment, and we are very grateful to The Michael J. Fox and Shake It Up Australia foundations for funding our research," Associate Professor Woodruff said.
A UQ collaboration including Kate Schroder has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research.